ArticleRevista clinica espanola2022
CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC study.
Article in Revista clinica espanola, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Severity Scores in SARS-CoV-2 Infection-A Comprehensive Bibliometric Review and Visualization Analysis.Epidemiologia (Basel, Switzerland) · 2026Review
- Forecasting COVID-19 inpatient mortality using fundamental parameters in resource-constrained settings: a countrywide multi-center cohort study.BMC infectious diseases · 2025Article
- Comparison of the Predictive Capacity of Oxygenation Parameters, Oxygenation Indices, and CURB-65 to Mortality, Mechanical Ventilation, and Vasopressor Support in Community-Acquired Pneumonia at Different Altitudes.Canadian respiratory journal · 2025Article
- Assessing the Utility of Prediction Scores PAINT, ISARIC4C, CHIS, and COVID-GRAM at Admission and Seven Days after Symptom Onset for COVID-19 Mortality.Journal of personalized medicine · 2024Article
- Malnutrition management of hospitalized patients with diabetes/hyperglycemia and COVID-19 infection.Reviews in endocrine & metabolic disorders · 2022Review
- The CURB65 score predicted 180-day mortality of non-small cell lung carcinoma patients with immune checkpoint inhibitor-associated pneumonitis: A pilot retrospective analysis.Frontiers in oncology · 2022Article
- CURB-65, qSOFA, and SIRS Criteria in Predicting In-Hospital Mortality of Critically Ill COVID-19 Patients; a Prognostic Accuracy Study.Archives of academic emergency medicine · 2022Article
- Characteristics and Clinical Course of Adult in Patients with SARS-CoV-2 Pneumonia at High Altitude.Canadian respiratory journal · 2021Article
- Differences in inflammatory markers between coronavirus disease 2019 and sepsis in hospitalised patients.Clinical epidemiology and global healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis article aims to assess the utility of CURB-65 in predicting 30-day mortality in adult patients hospitalized with COVID-19.
methodsThis work is a cohort study conducted between March 1 and April 30, 2020 in Ecuador.
resultsA total of 247 patients were included (mean age 60 ± 14 years, 70% men, overall mortality 41.3%). Patients with CURB-65 ≥ 2 had a higher mortality rate (57 vs. 17%, p < .001) that was associated with other markers of risk: advanced age, hypertension, overweight/obesity, kidney failure, hypoxemia, requirement for mechanical ventilation, or onset of respiratory distress.
conclusionsCURB-65 ≥ 2 was associated with higher 30-day mortality on the univariate (Kaplan-Meier estimator) and multivariate (Cox regression) analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.